{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:07:13Z","timestamp":1780106833694,"version":"3.54.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2025.102826","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:42:37Z","timestamp":1768416157000},"page":"102826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RFFL antisense oligonucleotides: A novel stabilization strategy to broaden the reach of CFTR modulator therapy"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102826_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic Fibrosis: A Review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102826_bib2","doi-asserted-by":"crossref","first-page":"102756","DOI":"10.1016\/j.omtn.2025.102756","article-title":"Antisense Oligonucleotide Targeting the Ubiquitin Ligase RFFL Potentiates CFTR Modulator Efficacy in CF Primary Bronchial Epithelial Cells","volume":"36","author":"Hinata","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102826_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","article-title":"Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase","volume":"44","author":"Okiyoneda","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2025.102826_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2006.06.041","article-title":"Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator","volume":"126","author":"Younger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102826_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fphar.2018.01100","article-title":"Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer","volume":"9","author":"Fukuda","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102826_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102826_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102826_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150433","article-title":"Enhanced CFTR modulator efficacy in F508del CFTR mouse organoids by ablation of RFFL ubiquitin ligase","volume":"733","author":"Hinata","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102826_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102826_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:16:00Z","timestamp":1780103760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253125003804"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102826","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RFFL antisense oligonucleotides: A novel stabilization strategy to broaden the reach of CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102826"}}